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Abstract
 
The CD8
 
  
 
T cell response to Epstein-Barr virus (EBV) is well characterized. Much less is
known about the evolution of the CD4
 
  
 
T cell response. Here we show that EBV stimulates a
primary burst of effector CD4
 
  
 
T cells and this is followed by a period of down-regulation. A
small population of EBV-specific effector CD4
 
  
 
T cells survives during the lifelong persistent
phase of infection. The EBV-specific effector CD4
 
  
 
T cells accumulate within a CD27
 
 
 
CD28
 
  
 
differentiation compartment during primary infection and remain enriched within this
compartment throughout the persistent phase of infection. Analysis of CD4
 
  
 
T cell responses
to individual epitopes from EBV latent and lytic cycle proteins confirms the observation that
the majority of the effector cells express both CD27 and CD28, although CD4
 
  
 
T cells specific
for lytic cycle antigens have a greater tendency to express CD45RA than those specific for the
latent antigens. In clear contrast, effector CD4
 
  
 
T cells specific for cytomegalovirus (CMV)
accumulate within the CD27
 
  
 
CD28
 
  
 
and CD27
 
  
 
CD28
 
  
 
compartments. There are striking
parallels in terms of the differentiation of CD8
 
  
 
T cells specific for EBV and CMV. The results
challenge current ideas on the definition of memory subsets.
Key words: immunity • antigens CD27 • antigens CD28 • Epstein-Barr virus • 
cytomegalovirus
 
Introduction
 
Antigen-experienced T cells comprise a heterogeneous
population with enormous diversity in terms of antigen
specificity, expression of cell surface molecules, and effec-
tor capacity. In the context of CD8
 
  
 
T cells an effort has
been made to understand this complexity by considering
cells as distributed between three differentiation compart-
ments defined by expression of the costimulatory mole-
cules CD27 and CD28 (1–7). A linear model of CD8
 
  
 
T
cell maturation has been proposed, with cells progressing
 
from a CD45RA
 
  
 
CD27
 
  
 
CD28
 
  
 
(naive) phenotype via
a CD45RA
 
  
 
CD27
 
  
 
CD28
 
  
 
(early antigen–experienced)
to a CD45RA
 
    
 
CD27
 
  
 
CD28
 
  
 
(intermediate antigen–
experienced), and then to a CD45RA
 
    
 
CD27
 
  
 
CD28
 
 
 
(late antigen–experienced) phenotype (6, 7).
Longitudinal studies show that EBV-specific CD8
 
  
 
T
cells accumulate within the CD27
 
  
 
CD28
 
  
 
and CD27
 
 
 
CD28
 
  
 
compartments during primary EBV infection (8, 9)
and remain enriched within these compartments during the
lifelong persistent phase of EBV infection (6, 9, 10). CD8
 
 
 
T cells specific for the latent proteins are more likely to be
enriched within the CD27
 
  
 
CD28
 
  
 
compartment whereas
those specific for lytic cycle proteins accumulate within
both CD27
 
  
 
CD28
 
  
 
and CD27
 
  
 
CD28
 
  
 
compartments.
HIV-specific CD8
 
  
 
T cells differentiate into the CD27
 
 
 
CD28
 
  
 
and CD27
 
  
 
CD28
 
  
 
compartments during primary
HIV infection but come to lie predominantly within the
CD27
 
  
 
CD28
 
  
 
compartment during the lifelong persistent
phase of HIV infection (6). During persistent CMV infec-
tion, CMV-specific CD8
 
  
 
T cells are enriched within the
CD27
 
  
 
CD28
 
  
 
compartment (6). Thus, memory CD8
 
  
 
T
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Abbreviations used in this paper:
 
 EBNA, EBV nuclear antigen; IM, infec-
tious mononucleosis; MOI, multiplicity of infection.T
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cells with different specificities accumulate in distinct dif-
ferentiation compartments. In this context, “memory” is
used as a term to describe the population of specific T cells
that persists after resolution of primary infection regardless
of their phenotypic and functional properties.
Investigation of the differentiation of virus-specific
CD8
 
  
 
T cells was facilitated by the use of multicolor flow
cytometry and fluorescent-labeled HLA peptide tetrameric
complexes, enabling the characterization of epitope-spe-
cific CD8
 
  
 
T cells in samples of peripheral blood. Similar
studies of the CD4
 
  
 
T cell response to viruses have been
hampered by paucity of reagents capable of identifying
CD4
 
  
 
T cells on the basis of specificity. Here we have ana-
lyzed CD4
 
  
 
T cell differentiation in the context of the im-
mune response to EBV. To detect virus-specific CD4
 
  
 
T
cells, we adapted an assay that has been developed to ana-
lyze the CD4
 
  
 
T cell response to human CMV (11–13)
and used a lysate of EBV-infected cells to stimulate samples
of PBMCs in vitro. Small populations of CD4
 
  
 
T cells
from EBV-seropositive, but not EBV-seronegative, donors
respond to stimulation by this lysate by expressing IFN-
 
 
 
.
We have used this assay to analyze the primary CD4
 
  
 
T
cell response to EBV and have gone on to examine the
memory CD4
 
  
 
T cell response to EBV in selected patients.
We have then extended the study to include an analysis of
memory EBV-specific CD4
 
  
 
T cells in healthy EBV-sero-
positive individuals and have compared these cells with
CMV-specific CD4
 
  
 
T cells in the same individuals. CD4
 
 
 
T cells characterized using these methods are, by definition,
part of the effector subset, as they are identified on the basis
of their capacity to express IFN-
 
  
 
after short-term stimula-
tion with antigen. The work has allowed us to characterize
the effector CD4
 
  
 
T cell response to EBV and compare the
phenotype of effector CD4
 
  
 
T cells specific for two differ-
ent herpesviruses.
 
Materials and Methods
 
Patients and Samples.
 
36 patients were identified during the
acute stage of infectious mononucleosis (IM) due to primary EBV
infection, using an EBV-specific latex agglutination test. Samples
of peripheral blood were taken immediately after diagnosis and, in
seven patients, 4 mo later. Peripheral blood was also taken from 28
healthy EBV-seropositive individuals and 5 healthy EBV-seroneg-
ative individuals. EBV serological status was determined by testing
first for the presence of EBV nuclear antigen (EBNA)1 IgG and
then, in individuals negative for this antibody, for EBV IgG. Two
samples of cord blood were also collected. PBMCs were separated
by centrifugation on a lymphoprep gradient (Nycomed Pharam)
and used in experiments immediately. The Oxfordshire Clinical
Research Ethics Committee approved this study.
 
Stimulation of PBMCs.
 
Freshly separated PBMCs were incu-
bated for 18 h in RPMI (GIBCO BRL) supplemented with 10%
fetal calf serum and 10 U/ml recombinant IL-2, either alone or in
the presence of an EBV-infected B cell lysate, a CMV-infected fi-
broblast cell lysate (both from East Coast Biologics, Inc.), or pep-
tides from EBV latent or lytic cycle proteins, including PQCRLT-
PLSRLPFGM, RPFFHPVGEADYFEY, NPKFENIAEGLRALL,
and TSLYNLRRGTALAI from EBNA1 (14), TVFYNIPPMPL
 
and PRSPTVFYNIPPMPL from EBNA2 (15 and unpublished
data), SDDELPYIDNMEPV (SDD) from EBNA3C (14), NFD-
VGGKKHQLDLDFGQLTP (NFD) from GP350 (unpublished
data), and pools of overlapping 20 mer peptides covering the amino
acid sequences of BMLF1, BZLF1, and GP350. All antigens were
used at a final concentration of 10 
 
 
 
g/ml. Brefeldin A (Sigma-
Aldrich) was added after 1 h at a final concentration of 5 
 
 
 
g/ml.
The incubation was performed in V-bottomed tubes at 37
 
 
 
C in the
presence of 5% CO
 
2
 
. The CMV-infected fibroblast cell lysate has
been extensively used as a tool for investigating responses to CMV.
The EBV-infected B cell lysate is derived from activated B cells in-
fected with the P3HR1 strain of EBV and enriched for viral pro-
teins. The manufacturers report that it contains proteins reactive
with antibodies to viral capsid and early and nuclear antigens. As
controls, PBMCs were also incubated with 10 
 
 
 
g/ml of a lysate
from uninfected B cells, selected from PBMCs using dynabeads
conjugated to anti-CD19 mAb, and with an uninfected fibroblast
cell lysate (Virusys).
 
ELISA to Detect EBV Proteins.
 
MaxiSorp plates were coated
with (a) the commercial EBV-infected B cell lysate, (b) a lysate
preparation of uninfected B cells, positively selected from PBMCs
using CD19-coated dynabeads, or (c) a lysate preparation of B cell
blasts that had been infected overnight with a recombinant vac-
cinia virus expressing BMRF1 (r-VV BMRF1) at a multiplicity of
infection (MOI) of 10:1 or (d) no protein. Plates were washed
with PBS/0.1% Tween and blocked with buffer containing 1%
BSA before being incubated with saturating concentrations of an-
tibodies specific for BZLF1 (DakoCytomation), BMRF1 (Viru-
sys), and LMP-1 (DakoCytomation), in blocking buffer. Antibody
binding was detected using ALK anti-IgG1 followed by the addi-
tion of 
 
p
 
-Nitrophenyl phosphate (Sigma-Aldrich).
 
Staining of PBMCs.
 
Cells were washed in PBS buffer contain-
ing 0.16% BSA and 0.1% sodium azide (PBA) and stained for 30
min on ice with saturating amounts of antibodies including
anti–CD45RA-FITC (BD Biosciences), anti–CD45RO-FITC
(DakoCytomation), anti–CD45RO-PE (BD Biosciences), anti–
CD27-FITC (BD Biosciences), anti–CD27-PE (BD Biosciences),
anti–CD62L-FITC (BD Biosciences), anti–CD57-FITC (BD Bio-
sciences), anti–CD28-FITC (BD Biosciences), anti–CD28-PE (BD
Biosciences), and anti–CD28-APC (BD Biosciences). Cells were
stained for CCR7 by incubating with anti–human CCR7 mAb
(BD Biosciences) and binding was detected by subsequent incuba-
tion with rabbit anti–mouse IgG-FITC (DakoCytomation). All an-
tibodies were diluted in PBA supplemented by 1% human serum.
Cells were then washed in PBA supplemented by 1% human serum
and 1% mouse serum, fixed, and permeabilized with cytofix-cyto-
perm (BD Biosciences), as per the manufacturer’s instructions. Ali-
quots of 10
 
6 
 
cells were stained with 0.1 
 
 
 
g anti–IFN-
 
 
 
–APC (BD
Biosciences) or with mouse IgG2a-APC (BD Biosciences) as a neg-
ative control. All antibodies were diluted in cytoperm buffer and
saturating amounts of anti–CD4-PerCP (BD Biosciences) and anti–
CD3-PE (DakoCytomation) or anti–CD8-PE (BD Biosciences)
and anti–CD3-PerCP (BD Biosciences) were also included in the
intracellular staining mix. After 60 min, cells were washed in cold
PBS and resuspended in PBS containing 1% formaldehyde and 1%
fetal calf serum. Analysis was performed on a FACSCalibur™ flow
cytometer (BD Biosciences) using CELLQuest™ software. Where
possible, 500,000 events were collected for analysis. Fewer cells
were available from some patients with IM and in these cases
200,000 events were collected. Gates were set on lymphocytes ac-
cording to their forward and side scatter characteristics. Using these
methods, we are able to detect populations of responding cells
present at frequencies as low as 0.03% CD4
 
  
 
T cells. In all but oneT
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experiment described here, the constitutive expression of IFN-
 
  
 
by
CD4
 
  
 
T cells was 
 
 
 
0.01%. In one patient with IM we found that
0.3% CD4
 
  
 
T cells expressed IFN-
 
  
 
directly ex vivo. For the pur-
poses of analysis this frequency was subtracted from that of CD4
 
  
 
T
cells responding after stimulation with the viral lysate, although it is
likely that the cells were EBV specific.
 
Results and Discussion
 
Detection of EBV-specific CD4
 
  
 
T Cells within Preparations
of PBMCs.
 
To characterize the CD4
 
  
 
T cell response to
EBV we developed an assay to detect EBV-specific T cells
within samples of peripheral blood. We used a commer-
cially available lysate prepared from EBV-infected B cells
and enriched for viral antigens as a source of EBV antigens.
By ELISA we confirmed the manufacturer’s reports that
the lysate contained both lytic cycle and latent proteins and
were able to detect BZLF1, BMRF1, and LMP-1. These
proteins were not detected in a sample of lysed uninfected
B cells (Fig. 1 a and unpublished data). The concentration
of BMRF1 within the commercial lysate was greater than
that found within a detergent lysate of B cells infected
overnight with r-VV BMRF1 at an MOI of 10:1 (Fig. 1 a).
Incubation of PBMCs taken from EBV-seropositive do-
nors, in R10 supplemented by the EBV-infected B cell ly-
sate, in the presence of brefeldin A, stimulated detectable
Figure 1. Detection of EBV-specific CD4  T cells in
samples of PBMCs. (a) BMRF1 was detected at higher
concentrations in the EBV-infected cell lysate preparation
( ) than in a lysate from B cells infected overnight with
r-VV-BMRF1 (MOI 10:1;  ). BMRF1 was not detected
in a lysate prepared from uninfected B cells ( ) or when
plates were not coated with protein (X). PBMCs from (b)
an EBV-seronegative and (c and d) an EBV-seropositive
donor were cultured in the presence of (b and d) lysate
from EBV-infected cells (EIBCL) or (c) lysate from unin-
fected B cells (UBCL). (e and f) PBMCs from a CMV-
seropositive donor were cultured in presence of (e) lysate
from uninfected fibroblasts (UFCL) or (f) lysate from
CMV-infected fibroblasts (CIFCL). Cells were stained for
expression of IFN-  and CD3, CD4, and CD8. A popula-
tion of cells within PBMCs from the EBV-seropositive
donor responded to the EIBCL and a population from
the CMV-seropositive donor responded to the CIFCL.
(g and h) Responding EBV-specific IFN- –expressing
cells were predominantly CD4  T cells.T
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IFN-
 
  
 
expression in a subset of lymphocytes (Fig. 1 d). In
contrast, PBMCs from these donors, when incubated in
R10 alone or with an uninfected B cell lysate, both in the
presence of brefeldin A, did not express IFN-
 
  
 
(Fig. 1 c
and unpublished data). Furthermore, we found that the ly-
sate did not stimulate lymphocytes, taken from any of five
EBV-seronegative adults or two samples of cord blood, to
express IFN-
 
  
 
(Fig. 1 b and unpublished data). Analysis of
responding lymphocytes in the EBV-seropositive donors
showed that they were CD3
 
  
 
T cells and that most ex-
pressed CD4 and not CD8 (Fig. 1, g and h). We observed
some down-regulation of CD4 by responding T cells, par-
ticularly at 18 h. The assay was more sensitive at 18 h com-
pared with 6 h, with higher numbers of CD4
 
  
 
T cells ex-
pressing detectable IFN-  at this time point. The type of
antigen preparation used would be expected to preferen-
tially stimulate a CD4  T cell response in vitro. Engage-
ment of CD8  T cells would require cross-presentation to
occur and this process was relatively inefficient under the
assay conditions used.
In parallel experiments we showed that culture of PBMCs
from a CMV-seropositive donor with a CMV-infected fi-
broblast cell lysate stimulated expression of IFN-  in a sub-
set of lymphocytes (Fig. 1 f). PBMCs from the same donor
did not express IFN-  after incubation with a lysate from
an uninfected fibroblast cell line or with medium alone
(Fig. 1 e and unpublished data).
The Magnitude of the CD4  T Cell Response to EBV during
Primary and Persistent Infection. This experimental proto-
col allowed us to probe the primary CD4  T cell response
to EBV in patients with acute IM. We studied 36 patients
and found that the frequency of responding CD4  T cells
ranged from 0.04 to 5.2% CD4  T cells (mean 1.4%; Fig.
2 a). Although the overall magnitude of the response might
be underestimated, the results show that primary infection
with EBV stimulates a significant, early CD4  T cell re-
sponse in vivo. The magnitude of the response is comparable
to the size of the CD4  T cell response to primary lympho-
cytic choriomeningitis virus or Listeria monocytogenes infec-
tion in mice and to HIV in humans (16–19). The size of
these responses is substantially lower than that of the primary
CD8  T cell response to the same pathogens (8, 19–22).
We obtained further specimens of PBMCs from seven
patients 4 mo after primary infection. The magnitude of
the response to the lysate was significantly lower at the sec-
ond time point than during primary infection in this cohort
(P   0.005; mean reduction of 4.2-fold; Fig. 2 a).
We went on to determine the frequency of CD4  T cells
that responded to the EBV-infected cell lysate within
Figure 2. Frequency and phenotype of EBV-specific CD4  T cells.
(a) The frequency of CD4  T cells that responded to the EBV-infected
B cell lysate in 36 patients with IM (Primary), in 7 patients 4 mo after
primary infection (Post-primary), and in 28 healthy EBV-seropositive
individuals (Persistent). A mean of 1.4% CD4  T cells responded during
the primary phase of infection, a mean of 0.22% CD4  T cells responded
4 mo later, and a mean of 0.34% CD4  T cells responded during the per-
sistent phase of infection. (b–f) PBMCs, taken from a patient with IM at
the time of his acute illness (left column) and then again 4 mo later (right
column), were cultured with lysate from EBV-infected cells. Cells were
stained for expression of (b) CD45RA, (c) CD45RO, (d) CD27, (e)
CD28, and (f) CD38, and then for expression of intracellular IFN-  and
CD4. Gates were set to include only CD4  lymphocytes. The percentages
of IFN- –expressing cells that stain with antibodies for each of the phe-
notypic markers are shown.T
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PBMCs from healthy EBV carriers. In 5 out of 28 EBV-sero-
positive individuals we could not detect populations of re-
sponding cells. In the remaining 23 individuals we found
that between 0.05 and 1.26% CD4  T cells responded to
the lysate (overall mean 0.34%; Fig. 2 a). The frequency of
EBV-specific CD4  T cells that we detected in these sero-
positive individuals was significantly lower than that detected
in patients suffering from primary infection (P   0.0001).
These results support the idea that EBV stimulates a pri-
mary CD4  T cell burst and that many of the responding ef-
fector cells die or lose functional capacity, leaving a smaller
population of effector cells to mediate protection during the
persistent phase of infection. Our experiments do not address
the fine specificity of the response, but a recently published
study shows that CD4  T cells specific for both lytic cycle
proteins and latent proteins contribute to the primary re-
sponse in patients with IM (23). It is possible that the domi-
nant CD4  T cell specificities change over time (22, 24).
Characterization of EBV-specific CD4  T Cells during Primary
and Persistent Infection. We characterized the EBV-specific
effector CD4  T cell response in more detail by investigat-
ing the phenotype of the responding T cells. Experiments
were performed on samples of PBMCs taken from 10 pa-
tients with IM due to primary EBV infection, 5 patients
4 mo later, and 10 healthy EBV-seropositive individuals.
Results from an experiment performed on patient
NS128 while he was suffering from IM and then 4 mo later
are shown in Fig. 2. During the primary phase of infection,
1.61% CD4  T cells responded to culture with the EBV-
infected cell lysate. The majority of these cells did not ex-
press CD45RA (Fig. 2 b) and did express CD45RO (Fig.
2 c). During the primary phase of infection most of the re-
sponding cells expressed CD27 (Fig. 2 d) and CD28 (Fig.
2 e) and had lost expression of CCR7 (unpublished data).
74% of the responding cells expressed CD38 (Fig. 2 f), sug-
gesting recent activation in vivo.
Figure 3. Phenotype of EBV- and CMV-specific CD4  T cells during persistent infection. (a–d) PBMCs, taken from a healthy individual who was
seropositive for both EBV and CMV, were cultured with lysate from EBV-infected cells (first column) or CMV-infected cells (second column). PBMCs
from a healthy individual were cultured in the presence of the SDD (third column) or the NFD peptide (fourth column). Cells were stained for expression
of (a) CD45RA, (b) CD45RO, (c) CD27, and (d) CD28, and then for expression of intracellular IFN-  and CD4. Gates were set to include only CD4 
lymphocytes. The percentages of IFN- –expressing cells that stain with antibodies for each of the phenotypic markers are shown.T
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4 mo later the frequency of responding CD4  T cells
had fallen to 0.33%. Most of these EBV-specific CD4  T
cells did not express CD38 (Fig. 2 f). In other respects the
phenotype of the cells was similar to that seen during the
primary phase of infection. The cells were predominantly,
but not exclusively, CCR7  (unpublished data).
Although some inter-individual variation was observed,
similar results were found when experiments were per-
formed on paired samples of PBMCs taken from four other
individuals during the primary and early persistent phases of
EBV infection. Overall, we found no significant difference
between frequency of expression of CD45 isoforms or of
CD27 and CD28 at the two time points. Furthermore, the
phenotype of EBV-specific CD4  T cells identified in sam-
ples of PBMCs from 10 healthy EBV-seropositive individ-
uals was not significantly different from that found in sam-
ples of PBMCs taken from the 5 patients shortly after
recovery from acute EBV infection. An example of this is
shown in the first column of Fig. 3. The majority of the
EBV-specific cells in healthy individuals with persistent
EBV infection continue to express CD45RO (Fig. 3 b)
rather than CD45RA (Fig. 3 a), and CD27 (Fig. 3 c) and
CD28 (Fig. 3 d). One of the healthy EBV-seropositive in-
dividuals studied has been infected for at least 15 yr and it is
likely that many others have also been persistently infected
for long periods of time. Thus, the phenotype of the EBV-
reactive effector CD4  T cells is established early during
the primary response and, apart from loss of expression of
markers of recent activation, shows little change during the
development or maintenance of the memory response. A
summary of the results of all 10 analyses performed on
blood taken during the primary and persistent phases of
EBV infection are shown in Fig. 4, a–d.
Characterization of CD4  T Cells Specific for Epitopes from
EBV Latent and Lytic Cycle Proteins. The frequency of
CD4  T cells specific for HLA class II–restricted epitopes
from EBV is usually low, with fewer than 1 in 10,000
PBMCs showing a detectable response to a given peptide
in ELISPOT assays. Furthermore, few class II–restricted
epitopes have been mapped within the EBV lytic cycle pro-
teins. These constraints limit ex vivo analysis of EBV
epitope-specific CD4  T cells. Nevertheless, we identified
some EBV-seropositive individuals in whom we could de-
tect populations of CD4  T cells that responded to stimula-
tion with peptides from EBV latent and lytic cycle proteins.
We characterized eight responses to peptides from latent
proteins, four of these being specific for EBNA1, three for
EBNA2, and one for EBNA3C, and six responses to pep-
tides from lytic cycle proteins, one specific for BZLF1, two
for BMLF1, and three for GP350. A representative example
of results from one donor, in whom 0.03% CD4  T cells
responded to a peptide epitope (SDD) from the latent pro-
tein EBNA3C and 0.16% CD4  T cells responded to a
peptide (NFD) from the lytic cycle protein GP350, is
shown in Fig. 3 (third and fourth columns). The epitope-
specific CD4  T cells were predominantly CD45RO ,
CD27 , and CD28  (Fig. 3, b–d). The majority did not
express CD45RA, although a clear minority of NFD-spe-
cific cells did express this CD45 isoform (Fig. 3 a). A sum-
mary of all results is shown in Fig. 4, e–h. Responses to
EBNA1 are considered separately from responses to the
other latent proteins studied (EBNA2 and EBNA3C) be-
cause EBNA1 might be expressed in lytic cycle as well as
latent infection (25). Most importantly, overall, the pheno-
type of CD4  T cells specific for individual epitopes from
EBV proteins was similar to that of CD4  T cells respond-
ing to the EBV-infected B cell lysate, with the majority of
cells expressing CD45RO, CD27, and CD28. Interest-
ingly, we found that mean CD45RA expression on CD4 
T cells specific for epitopes from the lytic cycle proteins was
higher than on CD4  T cells specific for epitopes from the
latent proteins (P   0.025 for lytic vs. EBNA2 and EBNA3
and P   0.02 for lytic vs. EBNA1, EBNA2, and EBNA3).
Identification of further, dominant class II–restricted epi-
Figure 4. CD4  T cell phenotype correlates with specificity. PBMCs
from 10 individuals with primary EBV infection and 10 individuals with
persistent EBV infection were cultured in vitro in R10 with lysate from
EBV-infected cells. PBMCs from 10 individuals with persistent CMV
infection were cultured with lysate from CMV-infected cells. Frequency
of expression of (a) CD45RA, (b) CD45RO, (c) CD27, and (d) CD28
on CD4  T cells that responded to the cell lysates by expressing IFN-  is
shown. PBMCs from healthy EBV-seropositive individuals were cultured
in the presence of peptides from the EBV latent proteins (EBNA2 or
EBNA3A), the EBV lytic cycle proteins (BZLF1, BMLF1, or GP350),
or EBNA1. Frequency of expression of (e) CD45RA, (f) CD45RO, (g)
CD27, and (h) CD28 on responding CD4  T cells is shown.T
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topes from EBV lytic cycle proteins is now required to en-
able additional studies to be performed to confirm this
observation. Notably, CD8  T cells specific for EBV lytic
cycle proteins are more likely to express CD45RA than
CD8  T cells specific for EBV latent proteins.
Comparison of the Phenotype of EBV-specific CD4  T Cells
with That of CMV-specific CD4  T Cells in Healthy Seroposi-
tive Individuals. The observation that EBV-specific effec-
tor cells are enriched within the CD27  subset of CD4  T
cells contrasts with previously published work on CD4  T
cell responses, in which effector cells have been found to
lack expression of CD27. To directly compare the pheno-
type of the CD4  T cells specific for two different patho-
gens, we identified four individuals who were seropositive
for both EBV and CMV and characterized the CD4  T
cells that responded to stimulation with the EBV and CMV
lysate preparations. Results from a typical experiment are
shown in Fig. 3. Despite the fact that the assays were per-
formed in an identical manner, we found differences in the
phenotype of the responding cells. The CMV-specific
CD4  T cells had usually lost expression of CD27 (Fig. 3 c)
and many had also lost expression of CD28 (Fig. 3 d). Sub-
populations of responding cells expressed CD45RA (Fig.
3 a). The response to CMV was studied in six additional
CMV-seropositive donors and the responding CD4  T
cells were again found to be predominantly CD27  and to
be heterogeneous with respect to expression of CD28. The
differences between expression of CD27 and CD28 by
EBV- and CMV-specific CD4  T cells was significant (P  
0.00001 and P   0.02, respectively). A summary of the re-
sults for all 10 donors studied are shown in Fig. 4, a–d.
Virus-specific Differentiation of CD4  T Cells. Multi-
color staining of PBMCs suggests that antigen-experienced
CD4  T cells can be considered as being distributed be-
tween three major, phenotypically distinct differentiation
compartments defined by expression of CD27 and CD28
(unpublished data). Cells within the CD27  CD28  com-
partment are more likely to express CCR7 whereas cells
within the CD27  CD28  compartment frequently express
CD57 and perforin (unpublished data). The patterns of ex-
pression of CD27 and CD28 on EBV- and CMV-specific
CD4  T cells (Fig. 4, c and d) suggest that CD4  T cells
specific for different viruses might be enriched within dis-
tinct differentiation compartments. To confirm this we
performed a more detailed phenotypic analysis of EBV-
and CMV-specific CD4  T cells in four donors, looking at
the phenotype of the CD28  and CD28  subsets. The ex-
periments were performed using EBV- and CMV-infected
cell lysates as sources of antigen. A representative example
of the results is shown in Fig. 5. The vast majority of the
EBV-specific CD4  T cells expressed CD27, CD28, and
CD45RO. Only a minority of cells had lost expression of
CD27, and a proportion of these had also lost expression of
CD28 (Fig. 5 a). Thus, these EBV-specific effector CD4 
T cells were highly enriched within the first (CD27 
CD28 ) differentiation compartment (Fig. 5 e).
In clear contrast, the CMV-specific CD4  T cells tended
to lack expression of CD27 and be heterogeneous with re-
spect to expression of CD28 (Fig. 5 a). In the example
shown, subpopulations of the CD28  CD4  T cells had re-
expressed CD45RA and down-regulated CD45RO (Fig.
5, b and c). A small population (20%) of CMV-specific cells
expressed low levels of both the CD45RO and RA iso-
Figure 5. Phenotype of CD28  and CD28  subsets of EBV- and
CMV-specific CD4  T cells during persistent infection. PBMCs from an
EBV- and CMV-seropositive healthy individual were cultured with lysate
from EBV-infected cells (left column) or from CMV-infected cells (right
column). Cells were stained for expression of CD28 and (a) CD45RA,
(b) CD45RO, (c) CD27, and then for expression of intracellular IFN- 
and CD4. Gates were set to include only CD4  lymphocytes that expressed
IFN- . The distribution of these cells between the quadrants is shown.
(e) A cross-sectional representation of proposed CD4  T cell differentia-
tion compartments. Naive cells express CD27, CD28, and CD45RA.
Antigen-experienced CD4  T cells predominantly lie in one of three
compartments, the first of which is characterized by expression of both
CD27 and CD28, the second by expression of CD28 but not CD27, and
the third by lack of expression of CD28 and CD27. EBV-specific CD4 
T cells are highly enriched in the first compartment. CMV-specific CD4 
T cells accumulate within the second and third compartments.T
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forms (Fig. 5 d). Overall, these CMV-specific CD4  effec-
tor T cells were enriched within the second (CD27 
CD28 ) and third (CD27  CD28 ) differentiation com-
partments (Fig. 5 e).
Concluding Comments. Different virus infections pose
different challenges to the immune system and variations in
initial antigen load, antigen persistence, antigen location,
and pathway of antigen presentation may all affect T cell
differentiation. Importantly, requirements for effective im-
mune control may differ between viruses and the differ-
ences in dominant T cell phenotypes may represent an ad-
aptation aimed at optimal control of virus infection.
In the context of virus-specific CD8  T cells, it has been
argued that sustained high antigen load may drive cells
from the early CD27  CD28  compartment through to the
late CD27  CD28  compartment. The observation that the
characteristic virus-specific phenotypes develop shortly af-
ter primary infection and are stable thereafter, even where
virus persists, argues against extent of antigen exposure as
the only factor influencing responding cell phenotype.
Moreover, recent evidence suggests that the emergence of
CMV-specific CD27  CD8  T cells within the circulation
actually correlates with a fall in viral load (26). One inter-
pretation of this is that the CD27  cells are generated dur-
ing primary infection, at which time they are distributed at
peripheral sites of CMV infection. As CMV infection be-
comes latent, these CD27  T cells emerge from the in-
fected tissues and appear within the blood (26).
In contrast, the EBV latent proteins might be expressed
intermittently throughout life in B cells, predominantly
within lymphoid tissue. Switch into EBV lytic infection
may also occur within B cells in the tonsillar environment.
It is therefore interesting that EBV-specific T cells are en-
riched, both during the primary and persistent phases of in-
fection, within the first differentiation compartment where
many cells express CCR7. By staining for IL-2 instead of
IFN- , we have been able to confirm the presence of pop-
ulations of EBV-specific CCR7  CD4  T cells (unpub-
lished data and 27). Such cells would be expected to recir-
culate not to peripheral tissue but to lymphoid tissues
where EBV-infected B cells express EBV antigens. Thus,
again the phenotype of the virus-specific CD4  T cells may
reflect the biology of virus infection.
CD27 and CD28 play an important role in modulating
the function of CD4  T cells. Expression of these mole-
cules influences the capacity of T cells to proliferate and/or
survive both in vitro and in vivo (3–5, 28–30). However,
our data do not support the idea that expression of CD27
and CD28 might be used as a means of identifying effector
T cells. We find that cells within each of the three pro-
posed CD4  T cell differentiation compartments are able to
express IFN-  after short-term stimulation in vitro. Thus,
CD4  T cells may have antigen-specific effector function
regardless of expression of CD27 or CD28.
In conclusion, we have dissected the phenotypic diver-
sity of the pool of memory CD4  T cells and have pro-
vided evidence in support of the idea that the phenotype of
antigen-experienced CD4  T cells correlates with their
specificity. Circulating EBV- and CMV-specific CD4  T
cells are enriched within different phenotypic compart-
ments in a manner that is clearly analogous to that seen for
their CD8  counterparts. Importantly, CD4  T cells with
effector capacity are present within each of the proposed
compartments. This work challenges the idea that the ef-
fector pool of CD4  T cells is derived from a resting
memory pool by a process of differentiation that involves
changes in expression of CD27, CD28, or CD45RA. Rather,
it suggests that the phenotypic heterogeneity of the mem-
ory pool reflects the different phenotypic characteristics of
T cells specific for different pathogens.
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